Cornerstone National Bank & Trust’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Cornerstone National Bank & Trust’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,000	Closed	-$136K	–	60
2022 Q4	$136K	Hold	25,000	–	–	0.08%	60
2022 Q3	$312K	Hold	25,000	–	–	0.17%	55
2022 Q2	$124K	Hold	25,000	–	–	0.06%	59
2022 Q1	$190K	Hold	25,000	–	–	0.08%	61
2021 Q4	$255K	Hold	25,000	–	–	0.11%	59
2021 Q3	$336K	Hold	25,000	–	–	0.15%	58
2021 Q2	$549K	Hold	25,000	–	–	0.24%	52
2021 Q1	$602K	Buy	+25,000	New	+$581K	0.28%	47

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cornerstone National Bank & Trust's GTHX Position: Q1 2023 in Review

Cornerstone National Bank & Trust sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 25,000 shares — an estimated $136K sold.

Cornerstone National Bank & Trust first reported a position in GTHX in Q1 2021 and held it in 8 quarters. The position peaked at $602K in Q1 2021. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

Cornerstone National Bank & Trust reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Cornerstone National Bank & Trust sold 25,000 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $136K.
Cornerstone National Bank & Trust first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Cornerstone National Bank & Trust's G1 Therapeutics, Inc. Common Stock position peaked at $602K in Q1 2021.
96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Cornerstone National Bank & Trust's 13F filing for Q1 2023, filed 28 Jan 2026.